Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Is there a vaccine for RSV or respiratory syncytial virus? After almost 60 years, several come at once

You might not have heard of respiratory syncytial virus, or RSV. But it caused more than 100,000 global deaths in 2019, making it a leading cause of death in children under one year old.

The Conversation

FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccine

The Food and Drug Administration has flagged Guillain-Barre syndrome, a rare neurological condition, as a potential risk for Pfizer’s respiratory syncytial virus vaccine.

Tribune News Service

RSV vaccines for babies, adults on the way. Here’s what could be coming.

Respiratory syncytial virus infects nearly everyone by age 2, usually causing nothing beyond cold symptoms. But it’s also the top cause of hospitalizations among kids under 5.

Chicago Sun-Times

From analysis to the latest developments in health,
read the most diverse news in one place.

The latest COVID-19 news and case numbers from around the states and territories

Here's a quick wrap of the COVID-19 news and case numbers from each Australian jurisdiction from the past week.

ABC News

3 Bargain Stocks to Buy Before the Crowd Catches On

A resilient economy and sticky inflation could lead Fed officials to hike interest rates higher than anticipated in the central bank’s next meeting. Although markets have been highly volatile amid concerns over the potential rate hikes and other macro headwinds, this has created an attractive opportunity for investors to scoop…

StockNews.com

A new bivalent COVID-19 booster rolls out next month. Here's what you need to know about the vaccine

All Australian adults who haven't had a COVID-19 booster or a confirmed case in the past six months are now eligible for an additional shot.

ABC News

Medics told mum cancer symptoms were Covid jab side effects - now she has months to live

Katie Pritchard is having to crowdfund £200,000 for private treatment after she was twice misdiagnosed, being told her symptoms may have been down to the Pfizer vaccine and even being insulted by the suggestion it was an STI

Daily Mirror

Read news from The Economist, FT, and more,
with one subscription

'Sobering': LA's Black, Latino kids under 5 are far behind on COVID-19 vaccinations

LOS ANGELES — Black and Latino children in Los Angeles County younger than 5 have COVID-19 vaccination rates in the single digits, reflecting a broad trend nationwide that has public health experts concerned and seeking ways to boost those figures.

Los Angeles Times

Game of Thrones star Iwan Rheon films in Swansea street transported back to 1994 for new drama Men Up

The film will follow the lives of five ordinary Welshmen as they go through an extraordinary journey which ultimately, and quite accidentally - led to the creation of the erectile dysfunction drug - Viagra

Wales Online

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

StockNews.com

Seoul donates next-gen Covid jabs

The Republic of Korea has donated over 500,000 doses of the bivalent Pfizer Covid-19 vaccine to Thailand to mark the 65th anniversary of diplomatic relations between the two countries.

Bangkok Post

3 Stocks You Won't Have Regrets About Buying in 2023

January’s robust macroeconomic reports indicate that the Fed might raise the interest rates for longer than expected. Also, the dramatic rise in consumer debt in the fourth quarter of 2022 is a red signal for the economy. Hence, fundamentally strong stocks Pfizer (PFE), CVS Health (CVS), and Universal Logistics (ULH)…

StockNews.com

Govt to roll out new vaccine next month

The Public Health Ministry will begin the roll-out of Pfizer's BA.1 bivalent Covid-19 vaccine next month, according to Dr Thares Krasanairawiwong, chief of the Department of Disease Control (DDC).

Bangkok Post

Covid Infection Gives Similar Immunity to Vaccination

The protection against Covid-19 from being previously infected lasts at least as long as that offered by vaccination, one of the largest studies conducted on the subject said on Friday. Ten months after getting Covid, people still had an 88 percent lower risk of reinfection, hospitalization and death, according to…

Asharq Al-Awsat

Get all your
news in one place.

100's of premium titles.
One news app.

ABC News

Risk of COVID death or hospitalisation 88 per cent lower for those previously infected, study finds

One of the largest studies conducted on COVID immunity finds that previous infections provide protection for as long as vaccination, but experts caution vaccines are still the safer option.

The Independent UK

Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial

US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine.

Los Angeles Times

What happens to COVID vaccines and drugs authorized for emergency use when health emergency ends?

On May 11, the central pillar of the country's pandemic response — the declaration of a national emergency that began March 1, 2020 — will come down. But Americans will continue to have access to the vaccines, drugs and medical devices that were authorized for emergency use against COVID-19, so…

StockNews.com

The Best Stock to Invest $1,000 in Right Now

Pfizer (PFE) played a pivotal role in developing vaccines and pills that helped the world return to normal from the COVID-19 pandemic. The company reported record revenue and earnings in fiscal 2022. Given the company’s solid growth prospects, it could be wise to invest in the stock right now. Keep…

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Era of ‘free’ COVID vaccines, test kits and treatments is ending. Who will pay the tab now?

Time is running out for free-to-consumer COVID-19 vaccines, at-home test kits and some treatments.

StockNews.com

3 Cream-of-the-Crop Stocks to Buy Today

With Russia’s plans to cut crude oil production threatening to tip an interest-rate-paranoid market into a fresh bout of volatility and sell-off, shares of fundamentally strong and profitable businesses, such as Taiwan Semiconductor Manufacturing Company (TSM), Walmart (WMT), and Pfizer (PFE), seem to be good investments now. Continue reading….

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

GOP paints a dark picture as 'weaponization' probe begins

Republicans have opened a new inquiry with a brazen attempt to portray the federal government as weaponized against Americans

The Independent UK

Pfizer, George Soros and Robert Mueller: GOP’s ‘weaponisation’ hearing goes after an array of conservative boogeymen

A committee hearing held as payback for probes into Donald Trump quickly devolved

WEKU

COVID test kits, treatments and vaccines won't be free to many consumers much longer

Insurers, employers, taxpayers and other consumers will all be affected as drugmakers move these products to the commercial market in May. How much you'll pay depends on your health insurance.

The Conversation

Haven't had COVID or a vaccine dose in the past six months? Consider getting a booster

Australians aged 18 and over will be eligible for a COVID booster from February 20 if they have not had a vaccine dose or infection in the past six months.

1 … 28 29 30 31

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Public Health Ministry

Food and Drug Administration

346 stories

PFE

345 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.